Puma Biotechnology Inc (NASDAQ:PBYI) shares gapped down before the market opened on Monday after BidaskClub downgraded the stock from a strong-buy rating to a buy rating. The stock had previously closed at $139.75, but opened at $127.20. Puma Biotechnology shares last traded at $103.00, with a volume of 5677100 shares trading hands.

A number of other equities research analysts have also commented on PBYI. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a report on Tuesday, July 18th. Citigroup Inc. reaffirmed a “buy” rating and issued a $114.00 target price on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $118.00 target price (up previously from $105.00) on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $117.00 target price (up previously from $100.00) on shares of Puma Biotechnology in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $130.67.

In other news, SVP Richard Paul Bryce sold 15,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $100.09, for a total value of $1,501,350.00. Following the completion of the sale, the senior vice president now owns 28,239 shares of the company’s stock, valued at $2,826,441.51. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.70% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC bought a new stake in Puma Biotechnology in the first quarter valued at approximately $257,000. Teachers Advisors LLC raised its position in shares of Puma Biotechnology by 2.0% during the first quarter. Teachers Advisors LLC now owns 145,197 shares of the biopharmaceutical company’s stock worth $5,401,000 after purchasing an additional 2,824 shares during the period. Legal & General Group Plc raised its position in shares of Puma Biotechnology by 2.8% during the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 249 shares during the period. Vanguard Group Inc. raised its position in Puma Biotechnology by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Puma Biotechnology by 17.3% during the 1st quarter. Geode Capital Management LLC now owns 232,371 shares of the biopharmaceutical company’s stock valued at $8,644,000 after purchasing an additional 34,190 shares during the last quarter. Institutional investors own 80.98% of the company’s stock.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same period in the prior year, the business earned ($1.11) earnings per share.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/14/puma-biotechnology-inc-pbyi-shares-gap-down-after-analyst-downgrade.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.